EvidenceHunt Secures €1.2 Million to Revolutionize AI in Medical Research
Amsterdam, Friday, 28 February 2025.
Amsterdam’s EvidenceHunt receives €1.2 million to expand its AI platform, speeding up medical literature analysis for 25,000 users globally, cutting professionals’ research time by 5 hours weekly.
Transforming Medical Research with AI
Amsterdam-based EvidenceHunt, founded in 2023 by Philippe Habets and Olivier Magnin [1], has developed an innovative AI-powered platform that is revolutionizing how medical professionals access and analyze research data. The platform enables users to obtain summarized, evidence-based answers within seconds, complete with verifiable sources [2]. For healthcare providers, medical scientists, and researchers, this technological advancement translates to significant time savings of up to 5 hours per week by eliminating manual searches through databases like PubMed [1][4].
Rapid Growth and Global Impact
Since its launch 18 months ago, EvidenceHunt has demonstrated remarkable growth, attracting 25,000 active users across more than 90 countries [3]. The platform processes over 150,000 questions monthly [1], delivering answers ten times faster than traditional research methods. The company has gained the trust of over 250 institutions, including prestigious organizations such as Pfizer, Google, UCL, University of Cambridge, and Columbia University [1].
Strategic Investment and Future Development
The €1.2 million funding round, announced on February 26, 2025 [7], was led by Amsterdam-based Keen Venture Partners, alongside Dff.ventures and Slimmer AI [1][2][3]. Notable angel investors including Jeroen Tas, former Chief Strategy and Innovation Officer at Philips, Dinko Valerio, former CEO of Crucell, and James Shannon, former Head of Global Drug Development at Novartis, have also joined the investment round [2]. As emphasized by CEO Philippe Habets, ‘Unlike generic AI platforms, our goal with EvidenceHunt is not to be a black box; it’s designed to empower users with transparency and reliability’ [1].
Enhanced Capabilities and Market Position
The fresh capital will enable EvidenceHunt to expand its platform capabilities, particularly in enterprise integration and team collaboration features [4]. Users will gain enhanced control over both input and output, with the ability to integrate various data types including protocols, guidelines, and unpublished research [4]. JC Heyneke from Slimmer AI highlights the platform’s potential, noting that ‘EvidenceHunt addresses a clear pain point for users across various segments worldwide’ through its integration of institutional workflows and advanced LLM technology [3].